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a non-selective α-adrenoceptor antagonist, from the group 
of pyrrolidin-2-one derivatives.
Methods The α1- and α2-adrenoreceptor affinities of the 
tested compound—1-(3-(4-(o-tolyl)piperazin-1-yl)propyl)
pyrrolidin-2-one had been investigated previously by means 
of the radioligand binding assay. In the present study, we 
extended the pharmacological profile characteristics of the 
selected molecule by additional intrinistic activity assays. 
Next, we investigated the influence of the tested compound 
on body weight, hyperglycemia, hypertriglyceridemia, blood 
pressure in the animal model of obesity induced by a high-
fat diet, and additionally we measured the spontaneous activ-
ity and body temperature.
Results The intrinistic activity studies revealed that the 
tested compound is a potent, non-selective antagonist of 
α1B and α2A-adrenoceptors. After the chronic administra-
tion of the tested compound, we observed reduced level of 
triglycerides and glucose in the rat plasma. Interestingly, the 
tested did not reduce the body weight and did not influence 
the blood pressure in normotensive animals. Additionally, 
the administration of the tested compound did not change the 
animals’ spontaneous activity and body temperature.
Conclusion Non-selective α-adrenoceptor antagonist 
seems to carry potential benefits in the improvement of the 
reduction of elevated glucose and triglyceride level. The lack 
of influence on blood pressure suggests that compounds with 
such a pharmacological profile may be particulary benefi-
cial for the patients with disturbed lipid and carbohydrate 
profile, who do not suffer from hypertension. These results 
are particulary valuable, since currently there are no safe 
α2A-adrenoceptor antagonist drugs available in clinical use 
with the ability to modulate hyperglycemia that would not 
affect blood pressure.
Abstract 
Purpose Previous studies have shown that several com-
ponents of the metabolic syndrome, such as hypertension, 
obesity or imbalanced lipid and carbohydrate homeostasis, 
are associated with the sympathetic nervous system over-
activity. Therefore, the inhibition of the adrenergic nervous 
system seems to be a reasonable and appropriate therapeu-
tic approach for the treatment of metabolic disturbances. It 
has been suggested that non-selective adrenoceptor antago-
nists could be particularly beneficial, since α1-adrenoceptor 
antagonists can improve disrupted lipid and carbohydrate 
profiles, while the inhibition of the α2-adrenoceptor may 
contribute to body weight reduction. The aim of the pre-
sent study was to investigate the metabolic benefits deriv-
ing from administration of a non-selective α-adrenoceptor 
antagonist from the group of pyrrolidin-2-one derivatives. 
The aim of the present study was to investigate the potential 
metabolic benefits deriving from chronic administration of 
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Introduction
The metabolic syndrome has been defined as a simultane-
ous occurrence of at least three out of five symptoms, such 
as impaired fasting glycaemia, abdominal obesity, elevated 
blood pressure, hypertriglyceridemia, and low levels of high 
density lipoprotein (HDL) [1]. The metabolic syndrome 
significantly increases the risk of developing serious con-
ditions, such as diabetes, coronary heart disease, ischemic 
stroke and artheroscleroris. Recent statistic reports have 
shown that the metabolic syndrome occurs in 20-25% of 
the adult population, and it has already reached epidemic 
proportions [2]. It constitutes a serious therapeutical chal-
lenge for the health care system in developed countries, and 
consequently there has been a great emphasis on developing 
effective and safe therapies.
Previous studies have revealed that several components 
of the metabolic syndrome are associated with an increased 
activation of the sympathetic nervous system. For instance, 
the adrenergic nervous system plays a key role in the induc-
tion and progression of high blood pressure, alteration of 
the cardiac output, peripheral vascular resistance as well 
as controlling the triglyceride and glucose metabolism [3]. 
It has been shown that the sympathetic nerve activation is 
much higher in patients with metabolic syndrome, compar-
ing with healthy subjects [4]. Moreover, when hypertension 
and obesity are present simultaneously, the sympathetic acti-
vation is significantly higher comparing with patients with a 
single disease [5]. Therefore, the inhibition of the adrenergic 
nervous system constitutes a suitable therapeutic approach 
for the treatment of the components of the metabolic syn-
drome [6].
The α-adrenoceptors seem to be an interesting molecular 
target, since many of the undesirable reactions are mediated 
via a stimulation of α-adrenoceptors, such as vasoconstric-
tion, and a release of free fatty acids and glucose. It has 
been postulated that particularly non-selective adrenoceptor 
antagonists may be beneficial for patients with metabolic 
syndrome [7]. The inactivation of α1-adrenoceptors causes 
vasodilatation and results in the reduction of blood pressure 
[8]. Moreover, the α1-adrenoceptor antagonists exert a posi-
tive effect on the lipid and carbohydrate profiles [9, 10]. The 
blockade of α2-adrenoceptors can lead to the reduction of 
body weight due to the activation of catecholamine release, 
sympathetic nervous system stimulation, and induction of 
lipolysis and thermogenesis [11]. It was also reported that 
the α2-adrenoceptor antagonists might favorably modulate 
the pancreatic function and abnormal insulin secretion [12].
Over the past few years, an extensive research on the 
pyrrolidin-2-one derivatives and its pharmacological activi-
ties has been conducted. The structure activity relationship 
within this group of compounds revealed that they possess 
a high affinity for the α-adrenoceptors and exert antagonis-
tic activity [13–16]. So far, the pyrrolidin-2-one derivatives 
demonstrated antiarrhythmic and antihypertensive properties 
[8, 17] and have been reported to reduce the body weight in 
the animal models of obesity [18].
In the present study, we investigated the effect of the 
non-selective α-adrenoceptor antagonist; 1-(3-(4-(o-tolyl)
piperazin-1-yl)propyl)pyrrolidin-2-one (EP-47) on the body 
weight, hyperglycemia, hypertriglyceridemia, spontaneous 
activity in animals with obesity induced by a high-fat diet, 
as well as blood pressure and temperature.
Materials and methods
Animals
The experiments were carried out on male Wistar rats 
(for the obesity studies, the animals’ body weight were 
150–160 g, for the blood pressure measurement, animals’ 
weight were: 220–260 g). The animals were housed in pairs 
in plastic cages in constant temperature-controlled facilities 
exposed to a light–dark cycle; water and food were available 
ad libitum. Control and experimental groups consisted of 
six to eight animals each. All experiments were conducted 
in accordance to the guidelines of the Animal Use and Care 
Committee of the Jagiellonian University and were approved 
for studies (2012, Poland; Permissions No 54/2012).
Determination of the intrinsic activity of the tested 
compound at the α1A‑adrenoreceptors 
and α1B‑adrenoreceptors
The intrinsic activity assay was performed according to 
the instructions of the manufacturer of the assay kit con-
taining ready-to-use cells with stable expression of the 
α1A-adrenoceptor (Invitrogen, Life Technologies) or α1B-
adrenoceptor (Perkin Elmer).
Determination of the intrinsic activity of the tested 
compound at the α2A‑adrenoreceptors 
and α2B‑adrenoreceptors
The intrinsic activity assay was performed according to 
the instructions of the manufacturer of the assay kit con-
taining ready-to-use cells with stable expression of the 
α2A-adrenoceptor (Invitrogen, Life Technologies) or α2B-
adrenoceptor (Perkin Elmer).
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Obesity induced by a fatty diet and influence on body 
weight
Male Wistar rats (150–160 g) were pair-housed and fed a 
fatty diet consisting of 40% fat blend (Labofeed B with 40% 
lard, Morawski, Manufacturer Feed, Poland) for 14 weeks, 
with water available ad libitum [19, 20]. Control rats were 
fed a standard diet (Labofeed B, Morawski Manufacturer 
Feed, Poland).
After 10 weeks, rats with obesity induced via their diet, 
were randomly divided into three equal groups that had 
the same mean body weight and were treated intraperito-
neally with the test compound at the following doses: 2 or 
5 mg/kg b.w./day and control group: vehicle–water 0.3 ml/
kg (diet-induced obesity control group) once daily in the 
mornings between 9:00 a.m. and 10:00 a.m. for 30 days. 
The rats with obesity (three groups) were maintained on a 
fatty diet throughout the treatment period (30 days). Con-
trol rats (one group) were maintained on a standard diet 
throughout 30 days, with intraperitoneal administration of 
vehicle–water.
Fatty feed composition (932 g of dry mass): protein 
193 g, fat (lard) 408 g, fiber 28.1 g, crude ash 43.6 g, cal-
cium 9.43  g, phosphorus 5.99  g, sodium 1.76  g, sugar 
76 g, magnesium 1.72 g, potassium 7.62 g, manganese 
48.7 mg, iodine 0.216 mg, copper 10.8 mg, iron 125 mg, 
zinc 61.3 mg, cobalt 0.253 mg, selenium 0.304 mg, vita-
min A 15,000 units, vitamin D3 1000 units, vitamin E 
95.3 mg, vitamin K3 3.0 mg, vitamin B1 8.06 mg, vitamin 
B2 6.47 mg, vitamin B6 10.3 mg, vitamin B12 0.051 mg, 
folic acid 2.05 mg, nicotinic acid 73.8 mg, pantothenic acid 
19.4 mg, choline 1578 mg.
Collecting peritoneal fat and the plasma
After the last 13th administration of the test compounds to 
animals, the feed was discontinued. On the 31st day, 20 min 
after intraperitoneal administration of heparin 1000 j/rat and 
70 mg/kg b.w. thiopental, plasma was collected from the left 
carotid artery of the animals. The peritoneal fat was removed 
and weighed.
The influence of the test compound on lipid 
and carbohydrate profiles in diet‑induced obese rats
To determine the glucose or triglyceride levels in the 
plasma, standard tests from Biomaxima S.A. (Poland) were 
used. The substrate was decomposed with the appropriate 
enzymes for the relevant product, which was converted to a 
colored compound. Coloration was proportional to their con-
centration. The absorbance was measured at a wavelength 
of 500 nm.
The influence of the tested compound on the locomotor 
activity after the chronic treatment in diet‑induced 
obese rats housed in pairs in home cages
The locomotor activity of rats treated with the test com-
pound was measured on the 1st, 21st and 29th day of the 
treatment with a special radio-frequency identification sys-
tem (RFID)—TraffiCage (TSE-Systems, Germany) [21]. 
The rats were housed in pairs in home cages, with feed and 
water available ad libitum. The animals had subcutaneously 
implanted transmitter identification, which enabled the 
presence and time spent in different areas of the cage to be 
recorded, and then the data were collected using a special 
computer program. The rats were treated intraperitoneally 
with a compound at a dose of 5 or 2 mg/kg b.w./day or with 
vehicle–water 0.3 ml/kg (control group) once a day in the 
mornings for 30 days. The locomotor activity was monitored 
for 24 h after administration of the test compound.
Determination of the effect of the tested compounds 
on blood pressure after a single administration 
in anesthetized Wistar rats
The rats were anesthetized with thiopental (70 mg/kg) via 
intraperitoneal injection. The left carotid artery was cannu-
lated with polyethylene tubing filled with heparin solution in 
saline to facilitate pressure measurements using a PowerLab 
Apparatus (ADInstruments, Australia). The blood pressure 
was measured both before intraperitoneal administration of 
the compound—time 0 min (control pressure) and 90 min 
thereafter. Pressure was measured in normotensive rats after 
a single administration of the test compound.
Determination of the effect of the test compound 
on the blood pressure during subchronic study 
in Wistar rats residing in natural housing conditions: 
telemetric method
The blood pressure of rats treated with the test compound 
was measured one the 1st and the 15th day, after 5 mg/kg 
b.w., intraperitoneally treatment with a special telemetric 
system—Stellar (TSE-Systems, Germany) [18].
Surgery The operation was performed over 30 min under 
sterile conditions. The rats were anesthetized with ketamine 
and xylasine (intramuscular injection: 100 and 10 mg/kg). 
Before the surgery and for 7 days after, the animals were 
additionally treated with cefuroxime (20 mg/kg/day) via 
intramuscular injection and ketoprofen (5 mg/kg/day) via 
intraperitoneal injection. The blood flow in the abdominal 
aorta was blocked temporarily and the tip of a transmitter 
for measuring pressure was inserted. The transmitter was 
sutured to the peritoneal cavity.
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The rats were individually caged for 2 weeks to heal after 
the surgical cut. Then, the animals were placed in pairs in 
cages to reduce their isolation stress. The blood pressure 
was measured: before intraperitoneal administration of the 
compounds—time 0 min and 23 h thereafter in the 1st and 
the 15th day.
Determination of the influence of the tested compound 
on the body’s temperature
The body temperature was measured using special log-
gers implanted subcutaneously (Star-Oddi, Island). Under 
general anesthesia (thiopental, 70 mg/kg, intraperitoneal), 
the loggers were inserted under the skin in the groin area 
and sutured with surgical thread. 24 h later, the baseline 
temperature was measured and then a starting compound 
was administered at a dose of 5 mg/kg b.w. The temperature 
measurement was performed for 24 h. The measurements 
were carried out every hour, with the first control 30 min 
after administration of compound. The test compound was 
given at 9:30 a.m. After 24 h, the loggers were removed and 
the body temperature data were read using a special set and 
software.
Statistical analysis
Statistical calculations were carried out with the GraphPad 
Prism 6 program. Results are given as arithmetic means with 
a standard error of the mean. Statistical significance was cal-
culated using a one-way ANOVA post hoc Dunnett’s Multi-
ple Comparison Test, two-way ANOVA post hoc Bonferroni 
test or Multiple t test. Differences were considered statisti-
cally significant at: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
Drugs and compounds
Heparin was delivered by Polfa Warszawa S.A. (Warsaw, 
Poland), while thiopental sodium was from Sandoz Interna-
tional (France). Brimonidine, terazosin, phentolamine (refer-
ence compounds for intrinsic activity test) were purchased 
from Sigma-Aldrich (St. Louis, Mo, USA).
The tested compound; 1-(3-(4-(o-tolyl)piperazin-1-yl)
propyl)pyrrolidin-2-one (EP-47) was synthesized in the 
Department of Physicochemical Drug Analysis, Chair of 
Pharmaceutical Chemistry, Faculty of Pharmacy, Jagiellon-
ian University Medical College, Kraków, Poland.
Results
Previously, we have identified a series of pyrrolidin-
2-one derivatives bearing an arylpiperazine fragment, 
which exerted a strong binding to α-adrenoceptors [22]. 
Among 14 compounds, we selected a molecule, namely; 
1-(3-(4-(o-tolyl)piperazin-1-yl)propyl)pyrrolidin-2-one 
(EP-47), which possess a strong affinity for α1- adrenocep-
tors with Ki = 95.5 ± 8.9 nM, and moderate affinity for 
α2-adrenoceptors Ki = 511.6 ± 34.8 nM. Figure 1 shows the 
chemical structure of the tested compound EP-47.
Intrinsic activity
The tested compound showed significant antagonistic prop-
erties at the α1B-adrenoceptor  (IC50 = 32.6 ± 0.69 nM) and 
weak at the α1A-adrenoceptor  (IC50 = 42.5 ± 11.2 μM). 
It also interacted antagonistically with α2A-adrenoceptor 
 (IC50  =  213  ±  32  nM). However, the functional 
response at the α2B-adrenoceptor was much weaker 
 (IC50 = 2.07 ± 0.69 μM).
The influence of the tested compound on the body 
weight of obese rats
The test compound administered at doses of 5 or 2 mg/kg 
b.w. intraperitoneally to rats fed on a high-fat feed did not 
cause a decrease in body weight gain compared to the obese 
rats (obesity control group = hight-fat feed + vechicle) [two-
way ANOVA F(32,315) = 0.2185, P = 0.9999]. The results are 
shown in Fig. 2.
The influence of the tested compounds on the amount 
of peritoneal adipose tissue of diet‑induced obese rats
In groups receiving the test compound, the amount of 
adipose tissue pads was lower than that in obese rats, but 
the difference was not statistically significant. There was 
also no difference between the amount of adipose tissue 
in the treated and the control group [one-way ANOVA 
F(3,21) = 7.521, P = 0.0013]. The results are shown in Fig. 3.
Influence of the test compound on triglyceride 
and glucose levels in diet‑induced obese rats
In animals treated with the test compound at a dose of 
5 mg/kg b.w., intraperitoneal, significantly lower blood 
Fig. 1  Formula for test compound: 1-(3-(4-(o-tolyl)piperazin-1-yl)
propyl)pyrrolidin-2-one
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glucose level was observed as compared to the group 
of obese animals treated with water [one-way ANOVA 
F(3,24) = 12.43, P = 0.0001]. The level of triglycerides was 
significantly lower in the group treated with the test com-
pound compared to the level determined in the plasma of 
the obese control group [one-way ANOVA F(3,24) = 5.153, 
P = 0.0068]. The results are presented in Fig. 4.
The influence of the tested compound on locomotor 
activity after chronic treatment in diet‑induced obese 
rats housed in pairs in home cages
The tested compound, at dose 5 mg/kg b.w., intraperito-
neal, had no effect on locomotor activity after both single 
and chronic administration in obese rats. The results are 
presented in Fig. 5.
Fig. 2  Effect of long-term administration of the α-adrenoceptor 
antagonist, 1-(3-(4-(o-tolyl)piperazin-1-yl)propyl)pyrrolidin-2-one, 
on body weight of diet-induced obese Wistar rats. The change in 
body weight in control (standard diet) and diet-induced obese Wistar 
rats, and diet-induced obese Wistar rats treated for 30 days with the 
tested compound. Results are mean ± SEM, n = 6. Multiple compari-
sons were by two-way ANOVA, post hoc Bonferroni test
Fig. 3  Weight of peritoneal fat after long-term administration of 
test compound in male Wistar rats in the obesity model. Results 
are mean ± SEM, n = 6. Multiple comparisons against the vehicle-
treated control group were by two-way ANOVA, post hoc Bonferroni 
test. Significant differences are denoted by *P < 0.05
Fig. 4  Effects of long-term administration of the test compound on 
plasma: glucose (a), triglyceride (b) levels in male Wistar rats in the 
obesity model. Results are mean  ±  SEM, n  =  6. Concentrations in 
plasma: mmol/l. Comparisons against the vehicle-treated control 
group (asterisk) or against the vehicle-treated obesity control group 
(wedge) were by one-way ANOVA, post hoc Bonferroni test. Signifi-
cant differences are denoted by ^P < 0.05, **P < 0.01
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The influence of the tested compound on blood pressure 
in anesthetized rats after single intraperitoneal 
administrations
The tested compounds at a dose 5 mg/kg b.w., intraperi-
toneal, did not significantly affect blood pressure after 
a single administration [two-way ANOVA; systolic: 
F(11,120) = 0.4434, P = 0.9332, diastolic: F(11,120) = 0.09905, 
P = 0.9999]. The test compound at a dose 2 mg/kg b.w., 
intraperitoneal, did not significantly affect blood pressure 
after a single administration [two-way ANOVA; systolic: 
F(11,108) = 0.01604, P = 0.9990, diastolic: F(11,108) = 0.1519, 
P = 0.9993]. The results are shown in Fig. 6.
The influence of the tested compound on the blood 
pressure in rats residing natural housing condition: 
the telemetric method
After single and 15th intraperitoneal administration of the 
tested compound at a dose of 5 mg/kg b.w. to rats residing in 
natural housing conditions, there was no significant changes 
in systolic and diastolic pressure, compared with rats that 
received water. The results are presented in Fig. 7.
Fig. 5  The influence of compound on locomotor activity after a 
single dose and chronic treatment in male Wistar rats in the obesity 
model. Locomotor Activity during 24  h period after treatment with 
test compound (5  mg/kg b.w.) or vehicle in diet-induced obese rats 
in 1st (a) and 29th (b) day of treatment. Activity is directly related to 
entrance to the various areas of the cage, n = 6 (Multiple t test)
Fig. 6  Changes in the blood pressure after single administration 
in anesthetized rats. Changes in systolic and diastolic blood pres-
sure after a single, intraperitoneal administration of test compound 
at doses: a 5  mg/kg b.w. or b 2  mg/kg to rats fed a standard diet. 
Mean ± S.E.M.; n = 6 (two-way ANOVA test)
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Influence of the test compound on the body 
temperature after a single administration
The test compound did not influence significantly the body 
temperature for 22 h after treatment in obese rats after 
one administration [two-way ANOVA; F(46,264) = 0.6823, 
P = 0.9407]. Results are shown in Fig. 8.
Discussion
Imbalanced lipid–carbohydrate homeostasis, the obesity, 
and the hypertension are the key components of the meta-
bolic syndrome. Due to the vast distribution of the adreno-
ceptors in the body, and its impact on the blood pressure, 
metabolism of triglycerides and glucose, the α-adrenoceptor 
antagonists may be useful in the treatment of many types 
of disorders. In this paper, we investigated the effect of the 
pyrrolidin-2-one derivative on the body weight, hyperglyce-
mia, hypertriglyceridemia and blood pressure in the animal 
model of obesity induced by a high-fat diet, measuring addi-
tionally the spontaneous activity and the temperature. The 
tested compound; 1-(3-(4-(o-tolyl)piperazin-1-yl)propyl)
pyrrolidin-2-one (EP-47) was selected from the library of 
previously synthesized and described structures, consider-
ing its non-selective affinity for the adrenoceptors with a 
preference towards the α1-adrenoceptors [22]. We extended 
the pharmacological profile characteristics of the selected 
molecule, by additional intrinistic activity assays, which 
revealed that the EP-47 is a potent antagonist of α1B and 
α2A-adrenoceptors. While designing the present study, we 
considered the recent literature data regarding the ability of 
α2A-adrenoceptor antagonists to indirectly induce the weight 
loss in animal models of obesity [18, 20, 23]. We postu-
lated that, since the tested compound is a α2-adrenoceptor 
Fig. 7  Changes in the blood pressure after administration in rats 
residing natural housing condition—telemetric methods. Changes 
in systolic (a) and diastolic (b) blood pressure after a single intra-
peritoneal administration of test compound at doses: 5 mg/kg b.w. 
to rats fed a standard diet. Changes in systolic (c) and diastolic (d) 
blood pressure after 15th times intraperitoneal administration of test 
compound at doses: 5 mg/kg b.w. to rats fed a standard diet. Percent-
age of pressure changes compared to the pressure measured before 
administration of the test compound. Mean ± S.E.M.; n = 6 (two-way 
ANOVA test)  
Fig. 8  The influence of test compound on temperature after a sin-
gle dose. The changes in temperature after a single, intraperito-
neal administration of compound or vehicle (0.3  ml) to non-obese 
rats; time 0 = 0.5 h before administration of compound (9.00 a.m.); 
Mean ± S.E.M.; n = 6; (two-way ANOVA test)
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antagonist, it is able to increase the release of noradrenaline, 
which stimulates the β-adrenoceptors located in adipocytes, 
and this could lead to increased lipolysis, thermogenesis and 
consequently to the weight loss. Therefore, we measured the 
influence on the body weight in the animal model of obesity 
induced by a high-fat diet, after the chronic administration 
of the tested compound. However, despite expected activ-
ity, the tested compound did not reduce the body weight in 
obese animals.
During the present study, in the animal model of obesity 
induced with a fatty diet, we observed a statistically signifi-
cant increase in the glucose or triglyceride levels in the col-
lected rat plasma [18, 20]. Since the tested compound exerts 
also antagonistic properties towards the α1-adreneoceptor, 
it could potentially improve the impaired lipid profile and 
carbohydrate metabolism [9, 10]. As a proof of concept, 
we observed a statistically significant reduction in the glu-
cose and triglyceride levels in animals treated with the 
tested compound. One can presume that this effect is asso-
ciated with the α1B-adrenoceptor inactivation, as the tested 
compound potently inhibited this particular subtype, while 
weakly affecting the α1A-subtype. However, in the literature 
there are no detailed studies which could clearly explain 
which α1-adrenoeptor subtype, contributes to the carbohy-
drate and lipid profile improvement. Therefore, we believe 
that the obtained results from our studies are particularly 
valuable.
On the other hand, the ability to balance the plasma 
glucose levels by the tested compound may also be asso-
ciated with the inhibition of α2A-adrenoceptors. The α2A-
adrenoceptors are widely distributed in the body, and are 
also present in the pancreatic islet β-cells [24]. During 
physiological conditions, catecholamines that act on the 
postsynaptic α2A-adrenoceptors located on the pancreatic 
islet β-cells, inhibit the insulin secretion and consequently 
increase the blood glucose levels [25]. Thus, the reduction 
of the α2A-adrenoceptor activity may facilitate the insulin 
secretion from the pancreatic islets and, as a result, reduce 
elevated glucose levels [26]. Previous studies demonstrated 
an improved insulin secretion in the presence of the non-
selective α2-adrenoceptor antagonist—yohimbine in dia-
betic patients [27], as well as the reduction of the glucose 
level by yohimbine in animal model of obesity induced by 
a high-fat diet [20] and in ob/ob mice (results submitted for 
publication). It would be interesting to consider the use of 
the α2A-adrenoceptor antagonist for the prevention or the 
treatment of the stress-induced hyperglycemia and associ-
ated with it; morbidity and mortality. Currently, there is no 
α2A-adrenoceptor antagonist in clinical use and the side-
effect profile of yohimbine is unacceptable to be considered 
as a potential treatment of the hyperglycemia.
In addition, the modest reduction of peritoneal fat piles 
was observed in the tested animals. The body fat mass was 
lower than the mass of adipose tissue in untreated obese 
rats. However, the body fat mass was higher than in the non-
obese control group. These results correlate with the lower 
levels of triglycerides in the plasma of the treated animals 
as compared to untreated animals. The observed reduction 
of the lipid and glucose levels after administration of the 
tested compound over a 30-day period, may suggest that its 
prolonged use could eventually lead to the reduction of the 
body weight in the test animals, as a result of a balanced 
lipid and carbohydrate economy which is often an important 
first step to weight loss.
The effect on the spontaneous activity of the animals was 
evaluated additionally. The modern equipment available in 
our laboratory enables us to precisely determinate the loca-
tion of an animal in the cage. Therefore, for the assessment 
of the spontaneous activity, we used the same group of ani-
mals for the measurement of body weight in obese animals. 
The changes in spontaneous locomotor activity could be a 
possible indicator of side effects of the tested compound 
[28]. In the present study, the tested compound did not sig-
nificantly affect spontaneous activity, thus indicating the 
absence of adverse behavioral reactions.
The temperature regulation in the brown adipocyte tis-
sue is mediated by the adrenergic system. Adipose tissue is 
highly innervated by the sympathetic nerve system, which 
becomes activated when exposed to cold and food. Since the 
activation of α2- and β3-adrenoceptors causes an opposite 
effect to each other, the α2/β3-adrenoreceptors ratio is very 
important, not only in the thermogenesis, but also in the 
control of the lipolysis in the white adipose tissue [29]. It 
has been shown that, the body temperature changes correlate 
with the thermogenesis [30] and α2A-adrenoceptor antago-
nists are able to increase the thermogenesis, which conse-
quently reduces the body weight [31]. The body is forced to 
use energy to recover the body temperature back to normal. 
In the present study, the tested compound did not signifi-
cantly affect the body temperature of the animals in the natu-
ral habitat, despite its ability to inhibit the α2A-adrenoceptor. 
The tested compound exhibits also antagonistic properties at 
the α1B-adrenoceptor. However, according to the literature 
data, both non-selective α1-adrenoceptor antagonists, such 
as prazosin, as well as selective α1A-adrenoceptor antago-
nists—RS100329 or cyclazosin—α1B-adrenoceptor antago-
nist do not affect the body temperature [32]. The obtained 
results are correlated with the lack of impact on body mass, 
but the mechanism of action remains unclear. Neverthe-
less, the application of an innovative telemetric system to 
measure the body temperature ensured of getting credible 
results, which were obtained during the measurement with-
out unnecessary interference in the animal behavior that 
could lead to the measurement-associated stress.
The tested compound did not impair the blood pressure 
in normotensive animals at the tested dose. We have not 
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observed a significant increase in the blood pressure, trig-
gered by excessive noradrenalin release [33], which is a 
characteristic for α2A-adrenoceptor antagonists [20]. Neither 
have we observed a sharp drop in the blood pressure due to a 
rapid vasodilatation caused by the α1B-adrenoceptor antago-
nists [8, 34]. The obtained results are likely related to the 
interesting pharmacological profile of the tested compound, 
which potently blocks these two subtypes of the adrenergic 
receptor. This sort of action can be specified as the func-
tional antagonism in terms of the blood pressure regula-
tion. The obtained results seem to be particulary interesting, 
considering that there are many clinical cases of patients 
with disturbed lipid and carbohydrate profile, but without 
hypertension. Additionally, there are also cases when high 
blood pressure is the main issue. However, it can be effec-
tively treated with first-line drugs in this indication, such as 
metabolically neutral angiotensin converting enzyme inhibi-
tors or beta-blockers that are metabolically adverse. This 
group of patients may need an add-on therapy with a drug, 
which improves the carbohydrate and lipid profiles, without 
interfering with blood pressure.
Although the obtained results are interesting regarding 
the potential treatment of patients with the metabolic syn-
drome, authors have recognized the following limitation of 
the conducted studies:
1. The insulin levels were not determined at the end of the 
experiment. Such analysis would be valuable, since α2-
adrenoceptor antagonists might favorably modulate the 
pancreatic function and the abnormal insulin secretion 
[26]. The determination of the insulin level would clar-
ify whether the reduced blood glucose level observed 
after the administration of the test compound, resulted 
from the insulin release mediated via α2A-adrenoceptors. 
This issue will be considered in our future studies.
2. The determination of circulating catecholamine lev-
els at the end of the study would be valuable, since 
α2-adrenoceptor antagonists enhance the release of 
catecholamines [11] and thus could induce potential 
negative cardiovascular effects. Circulating catecho-
lamines bind to the β-adrenoceptors, and a long-term 
cardiac stimulation of the β-adrenoceptor causes cardiac 
hypertrophy and dysfunction. The cardiac remodeling 
is also a compensation process, in which the expres-
sion of β-adrenoceptors is down-regulated to prevent 
the receptor from over-activation in the heart [35]. Adr-
energic receptors are readily susceptible to changes in 
the density and sensitivity. Depending on the condition, 
constant stimulation or blockade may lead to its down 
or up-regulation. A compound which is able to enhance 
the release of catecholamines through the stimulation 
of the beta-adrenergic receptors in the heart, may ini-
tially induce a desirable inotropic effect. However, the 
long-term stimulation of the β-adrenergic receptors, 
may lead to a decrease in receptor density and sensitiv-
ity, and thus adversely affect the existent heart failure. 
During the heart failure, the amount and sensitivity of 
adrenoceptors is pathologically reduced, thus chronic 
administration of an α2-adrenoceptor antagonist that 
increases the release of catecholamines seems to be a 
relatively unfavorable reaction. Therefore, one may wish 
to determinate additional changes in the adrenoceptors 
density in the heart, after chronic administration of the 
test compound.
3. Although the effect of the tested compound on the blood 
pressure using the telemetric method has been determi-
nated, it would be interesting additionally to evaluate 
the direct influence of the tested compound on vascular 
contractility. This study would reveal whether the test 
compound is able to dilate the blood vessels by block-
ing the α1-adrenoceptors. Additionally, one may wish 
to evaluate the influence on the blood pressure in the 
animal model of hypertension.
4. Since α1-adrenoceptor antagonist enhances ischaemia-
induced neo-angiogenesis independently of vasodila-
tation [36], it would be interesting to determine the 
influence of the tested compound on the vascular 
endothelium and the angiogenesis process.
Nevertheless, all the issues listed above will be addressed 
in our future studies.
Conclusion
The present study indicated that a non-selective α1B-/α2A-
adrenoceptor antagonist; 1-(3-(4-(o-tolyl)piperazin-1-yl)
propyl)pyrrolidin-2-one effectively reduced the elevated glu-
cose and triglyceride levels in the animal model of obesity 
induced by a high-fat diet. The tested compound only mod-
erately reduced the amount of peritoneal body fat. It neither 
affected the body temperature nor caused any disturbance in 
the spontaneous activity and the blood pressure. The lack of 
influence on blood pressure is particulary significant, since 
currently there are no α2A-adrenolytic agents available in 
clinical use which would not impair blood pressure. There-
fore, the search for novel molecules with a similar activity 
profile to the tested compound, seems to be a promising 
strategy regarding the potential treatment of hyperglycemia, 
hyperlipidemia induced by a high-fat diet. Maintaining sta-
ble euglycemia is one of the aims of an effective therapy of 
the metabolic syndrome as well as acute cardiac conditions, 
such as myocardial infarction, as it may significantly reduce 
the risk of cardiac complications in patients.
We believe that non-selective α1B-/α2A-adrenoceptor 
antagonists might have a potential in the treatment of the 
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metabolic syndrome, therefore 1-(3-(4-(o-tolyl)piperazin-
1-yl)propyl)pyrrolidin-2-one requires further extended stud-
ies to explore its full pharmacological profile.
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